Sayaka Hasegawa

Assessment of patient-reported outcomes for sleep status and daytime functioning with vornorexant administration: results from a randomized phase 3 pivotal study

Abstract Purpose To investigate the effects of vornorexant, a novel dual orexin receptor antagonist developed for the treatment of insomnia, on patient-reported sleep status and daytime functioning in a randomized, double-blinded, placebo-controlled pivotal phase 3 trial. Methods...